Heart failure is the 4th leading cause of 30-day hospital readmissions and the #1 cause of Medicare patient hospital readmissions.

Cardiac Resynchronization Therapy (CRT) is effective for indicated heart failure patients: reducing mortality and hospitalizations, and improving quality of life.

AdaptivCRT® reduces 30-day hospital readmissions for heart failure by nearly half.

Heart failure affects 5.1 million Americans and results in more than 1 million hospitalizations yearly.

On average, heart failure patients are readmitted 1.23 times in year one*; repeated hospitalizations are associated with increased mortality.

On average, a heart failure admission costs a hospital $8,184.

Hospitals incurred $227 million in Medicare readmission penalties in FY2014.

CRT reduces heart failure hospitalizations by 52%.

AdaptivCRT® preserves normal heart rhythms and adapts to patient needs, further reducing the risk of heart failure hospitalizations and death by 43%.

AdaptivCRT® is a Medtronic-exclusive therapy.

* Year after their initial diagnosis or heart failure destabilization


